Fluvoxamina [Inn-Spanish] en es it fr

Fluvoxamina [Inn-Spanish] Brand names, Fluvoxamina [Inn-Spanish] Analogs

Fluvoxamina [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Fluvoxamina [Inn-Spanish] Chemical_Formula


Fluvoxamina [Inn-Spanish] RX_link


Fluvoxamina [Inn-Spanish] fda sheet

Fluvoxamina_[Inn-Spanish] FDA

Fluvoxamina [Inn-Spanish] msds (material safety sheet)

Fluvoxamina_[Inn-Spanish] MSDS

Fluvoxamina [Inn-Spanish] Synthesis Reference

Neth. pat. Appl. 7503310; H. B. A. Welle, V. Classen, U.S. pat. 4085225

Fluvoxamina [Inn-Spanish] Molecular Weight

318.335 g/mol

Fluvoxamina [Inn-Spanish] Melting Point

120-122.5 oC

Fluvoxamina [Inn-Spanish] H2O Solubility

No information avaliable

Fluvoxamina [Inn-Spanish] State


Fluvoxamina [Inn-Spanish] LogP

No information avaliable

Fluvoxamina [Inn-Spanish] Dosage Forms


Fluvoxamina [Inn-Spanish] Indication

For treatment of depression and for Obsessive Compulsive Disorder (OCD)

Fluvoxamina [Inn-Spanish] Pharmacology

Fluvoxamine is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of Fluvoxamine are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that Fluvoxamine is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Fluvoxamine has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of Fluvoxamine was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Fluvoxamine does not inhibit monoamine oxidase.

Fluvoxamina [Inn-Spanish] Absorption

Well absorbed, bioavailability of fluvoxamine maleate is 53%.

Fluvoxamina [Inn-Spanish] side effects and Toxicity

Side effects include anorexia, constipation, dry mouth, headache, nausea, nervousness, skin rash, sleep problems, somnolence, liver toxicity, mania, increase urination, seizures, sweating increase, tremors, or Tourette's syndrome.

Fluvoxamina [Inn-Spanish] Patient Information

No information avaliable

Fluvoxamina [Inn-Spanish] Organisms Affected

Humans and other mammals